

Shiqi Peng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8459218/publications.pdf>

Version: 2024-02-01

63
papers

943
citations

516215

16
h-index

500791

28
g-index

87
all docs

87
docs citations

87
times ranked

1175
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and cytotoxic activities of \hat{I}^2 -carboline amino acid ester conjugates. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 6998-7010.	1.4	102
2	Novel N-(3-carboxyl-9-benzyl- \hat{I}^2 -carboline-1-yl)ethylamino acids: Synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4153-4161.	2.6	85
3	A class of oral N-[(1S,3S)-1-methyl-1,2,3,4-tetrahydro- \hat{I}^2 -carboline-3-carbonyl]-N $\hat{a}^{\epsilon 2}$ -(amino-acid-acyl)hydrazine: Discovery, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3237-3249.	2.6	43
4	Nanosized Aspirin-Arg-Gly-Asp-Val: Delivery of Aspirin to Thrombus by the Target Carrier Arg-Gly-Asp-Val Tetrapeptide. <i>ACS Nano</i> , 2013, 7, 7664-7673.	7.3	41
5	Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 4761-4774.	1.4	40
6	Lipid rafts-mediated endocytosis and physiology-based cell membrane traffic models of doxorubicin liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016, 1858, 1801-1811.	1.4	38
7	Implications for blood-brain-barrier permeability, in vitro oxidative stress and neurotoxicity potential induced by mesoporous silica nanoparticles: effects of surface modification. <i>RSC Advances</i> , 2016, 6, 2800-2809.	1.7	30
8	A new class of anti-thrombosis hexahydropyrazino-[1,6]pyrido-[3,4-b]-indole-1,4-dions: Design, synthesis, logK determination, and QSAR analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5672-5693.	1.4	29
9	A Class of 3- <i>S</i> -2-Aminoacyltetrahydro- \hat{I}^2 -carboline-3-carboxylic Acids: Their Facile Synthesis, Inhibition for Platelet Activation, and High in Vivo Anti-Thrombotic Potency. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3106-3116.	2.9	28
10	A class of novel N-(3S-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-l-amino acid derivatives: their synthesis, anti-thrombotic activity evaluation, and 3D QSAR analysis. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4904-4919.	2.6	27
11	A class of novel Schiff \hat{e}^{TM} s bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2165-2172.	1.4	25
12	A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6220-6229.	1.4	25
13	In vitro inhibition of fatty acid synthase by 1,2,3,4,6-penta-O-galloyl- \hat{I}^2 -d-glucose plays a vital role in anti-tumour activity. <i>Biochemical and Biophysical Research Communications</i> , 2014, 445, 346-351.	1.0	25
14	A class of novel N-(1-methyl- \hat{I}^2 -carboline-3-carbonyl)-N $\hat{a}^{\epsilon 2}$ -(aminoacid-acyl)-hydrazines: Aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5598-5608.	2.6	24
15	Novel N-(3-carboxyl-9-benzylcarboline-1-yl)ethylamino acids: synthesis, anti-proliferation activity and two-step-course of intercalation with calf thymus DNA. <i>Molecular BioSystems</i> , 2007, 3, 855.	2.9	22
16	2,3-Diamino acid modifying 3S-tetrahydroisoquinoline-3-carboxylic acids: Leading to a class of novel agents with highly unfolded conformation, selective in vitro anti-platelet aggregation and potent in vivo anti-thrombotic activity. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 1536-1554.	1.4	20
17	Preparation and Characterization of RGDS/Nanodiamond as a Vector for VEGF-siRNA Delivery. <i>Journal of Biomedical Nanotechnology</i> , 2015, 11, 70-80.	0.5	16
18	Loading cisplatin onto 6-mercaptapurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3933-3946.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1195-1204.	0.8	16
20	A class of Trp-Trp-AA-OBzl: Synthesis, in vitro anti-proliferation/in vivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3410-3419.	2.6	15
21	Aqueous extract of <i>Rabdosia rubescens</i> leaves: forming nanoparticles, targeting P-selectin, and inhibiting thrombosis. <i>International Journal of Nanomedicine</i> , 2015, 10, 6905.	3.3	14
22	RGD-peptides modifying dexamethasone: to enhance the anti-inflammatory efficacy and limit the risk of osteoporosis. <i>MedChemComm</i> , 2015, 6, 1345-1351.	3.5	14
23	RGDS covalently surfaced nanodiamond as a tumor targeting carrier of VEGF-siRNA: synthesis, characterization and bioassay. <i>Journal of Materials Chemistry B</i> , 2015, 3, 9260-9268.	2.9	13
24	Cu ²⁺ -RGDFRGDS: exploring the mechanism and high efficacy of the nanoparticle in antithrombotic therapy. <i>International Journal of Nanomedicine</i> , 2015, 10, 2925.	3.3	11
25	BPIC: A novel anti-tumor lead capable of inhibiting inflammation and scavenging free radicals. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1146-1150.	1.0	11
26	Design, synthesis, and testing of an isoquinoline-3-carboxylic-based novel anti-tumor lead. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4434-4436.	1.0	11
27	Tetrahydro- β -carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications. <i>Journal of Materials Chemistry B</i> , 2016, 4, 1384-1397.	2.9	11
28	Synthesis, nano-features, ex vivo anti-platelet aggregation and in vivo antithrombotic activities of poly-L-lysine-L-aspartyl-L-arginine. <i>MedChemComm</i> , 2012, 3, 102-108.	3.5	10
29	Novel nano-materials, RGD-tetrapeptide-modified 17 β -amino-11 β -hydroxyandrost-1,4-diene-3-one: synthesis, self-assembly based nano-images and in vivo anti-osteoporosis evaluation. <i>Journal of Materials Chemistry</i> , 2012, 22, 4652.	6.7	10
30	IQCA-TASS: a nano-scaled P-selectin inhibitor capable of targeting thrombus and releasing IQCA/TARGD(S)S in vivo. <i>Journal of Materials Chemistry B</i> , 2017, 5, 917-927.	2.9	10
31	Self-complexation and complexation-controlled target cancer therapy. <i>MedChemComm</i> , 2012, 3, 1059.	3.5	9
32	The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action. <i>Molecular BioSystems</i> , 2012, 8, 2672.	2.9	9
33	Nano-scaled MTCA-KKV: for targeting thrombus, releasing pharmacophores, inhibiting thrombosis and dissolving blood clots in vivo. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 4817-4831.	3.3	9
34	Development of three-component conjugates: to get nano-globes with porous surfaces, high in vivo anti-osteoporosis activity and minimal side effects. <i>Journal of Materials Chemistry</i> , 2012, 22, 21740.	6.7	8
35	DHDMIQK(KAP): a novel nano-delivery system of dihydroxyl-tetrahydro-isoquinoline-3-carboxylic acid and KPAK towards the thrombus. <i>Journal of Materials Chemistry B</i> , 2016, 4, 5991-6003.	2.9	8
36	A novel lead of P-selectin inhibitor: Discovery, synthesis, bioassays and action mechanism. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4631-4636.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Docking of THPDTP1: to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent. <i>Oncotarget</i> , 2018, 9, 268-281.	0.8	8
38	Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 1139-1158.	3.3	8
39	<p>RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 7263-7279.	3.3	8
40	Small molecule PZL318: forming fluorescent nanoparticles capable of tracing their interactions with cancer cells and activated platelets, slowing tumor growth and inhibiting thrombosis. <i>International Journal of Nanomedicine</i> , 2015, 10, 5273.	3.3	7
41	Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2097-2110.	2.0	7
42	Energy minimized crystal structures of P-selectins based on molecular dynamics simulation: leading to two average structures capable of designing anti-thrombotic agents. <i>MedChemComm</i> , 2013, 4, 1066.	3.5	6
43	N-((3-hydroxymethyl-β-carboline-1-yl-ethyl-2-yl)-L-Phe: development toward a nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 225-239.	2.0	6
44	5-(Bis(3-(2-hydroxyethyl)-1H-indol-2-yl)methyl)-2-hydroxybenzoic acid (BHIMHA): showing a strategy of designing drug to block lung metastasis of tumors. <i>Drug Design, Development and Therapy</i> , 2016, 10, 711.	2.0	5
45	Discovery of DEBIC to correlate P-selectin inhibition and DNA intercalation in cancer therapy and complicated thrombosis. <i>Oncotarget</i> , 2018, 9, 32119-32133.	0.8	5
46	<p>13-[CH ₂ CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10651-10662.	1.0	5
47	<p>Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 465-481.	3.3	5
48	N-[2(3-Carboxyl-9-benzyl-carboline-1-yl)ethyl-1-yl]-amino acids: correlation of spectral property with in vivo anti-tumor activity. <i>Medicinal Chemistry Research</i> , 2012, 21, 116-123.	1.1	4
49	RGD(F/S/V)-Dex: towards the development of novel, effective, and safe glucocorticoids. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1059.	2.0	4
50	Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5114-5118.	1.0	4
51	Dimethyl 2,2′-[2,2′-(ethane-1,1-diyl)bis(1H-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 7835-7844.	3.3	4
52	<p>Development of 13-Cys-BBR as an Agent Having Dual Action of Anti-Thrombosis and Anti-Inflammation</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2187-2197.	2.0	4
53	A class of novel AA-Trp-Trp-OBzl: synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and intercalation mechanism. <i>MedChemComm</i> , 2011, 2, 126-131.	3.5	3
54	ATIQCTPC: a nanomedicine capable of targeting tumor and blocking thrombosis in vivo. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 4415-4431.	3.3	3

#	ARTICLE	IF	CITATIONS
55	Design, synthesis, and in vivo evaluations of benzyl N ¹ -nitro-N ¹ -(9H-pyrido[3,4-b]indole-3-carbonyl)-L-argininate as an apoptosis inducer capable of decreasing the serum concentration of P-selectin. <i>MedChemComm</i> , 2016, 7, 1730-1737.	3.5	2
56	Heptapeptide-based modification leading to enhancing the action of MTCA on activated platelets, P-selectin, GPIIb/IIIa. <i>Future Medicinal Chemistry</i> , 2018, 10, 1957-1970.	1.1	2
57	BCESA: a nano-scaled intercalator capable of targeting tumor tissue and releasing anti-tumoral β -carboline-3-carboxylic acid. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 3027-3041.	3.3	2
58	Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway. <i>Scientific Reports</i> , 2020, 10, 15729.	1.6	2
59	Mechanism of forming trimer, self-assembling nano-particle and inhibiting tumor growth of small molecule CIPPCT. <i>MedChemComm</i> , 2014, 5, 1634-1643.	3.5	1
60	Modifying tetramethyl-nitrophenyl-imidazoline with amino acids: design, synthesis, and 3D-QSAR for improving inflammatory pain therapy. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2329.	2.0	1
61	Discovery of novel (6S/12aS)-heptachpyridone capable of inhibiting thrombosis in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127440.	1.0	1
62	ATIQTTPC targeting MMP-9: a key step to slowing primary tumor growth and inhibiting metastasis of lewis lung carcinoma in vivo. <i>Oncotarget</i> , 2017, 8, 63881-63889.	0.8	1
63	Cholyl-L-lysine-carboxylbutyryl adriamycin prodrugs targeting chemically induced liver injury. <i>Journal of Materials Chemistry B</i> , 2017, 5, 470-478.	2.9	0